Technology
Health
Biotechnology

Achieve Life Sciences

$3.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.34 (-8.88%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACHV and other stocks, options, ETFs, and crypto commission-free!

About

Achieve Life Sciences, Inc. Common Shares, also called Achieve Life Sciences, is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Read More Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Employees
13
Headquarters
Vancouver, British Columbia
Founded
1991
Market Cap
23.46M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
983.64K
High Today
$3.78
Low Today
$3.47
Open Price
$3.77
Volume
137.34K
52 Week High
$14.31
52 Week Low
$1.04

Collections

Technology
Health
Biotechnology
Medical
Pharmaceutical
Canada
North America

News

Yahoo FinanceMay 7

Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019

SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its first quarter 2019 financial results on Wednesday, May 15, 2019 . Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and...

266
Yahoo FinanceApr 26

ACHV: Final Enrollee, Final Visit

293
Markets InsiderApr 24

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's O...

419

Earnings

-$1.82
-$1.29
-$0.77
-$0.24
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.63 per share
Actual
-$0.88 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.